

For Immediate Release

Company name: DAIICHI SANKYO COMPANY, LIMITED

Representative: Joji Nakayama, President and CEO

(Code no.: 4568, First Section, Tokyo, Osaka and Nagoya Stock Exchanges)

Please address inquiries to Noriaki Ishida, Corporate Officer,

Vice President, Corporate Communications Department

Telephone: +81-3-6225-1126

<http://www.daiichisankyo.com>

**Daiichi Sankyo Submits Supplemental Application for Additional Indication of  
Anticancer Agent Topotecin® Intravenous Drip Infusion 40mg, 100mg**

**Tokyo, Japan (May 31, 2013)** – Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that it has submitted a supplemental new drug application to Japan's Ministry of Health, Labor and Welfare (hereafter, MHLW) for an additional indication and dosage for Topotecin® intravenous drip infusion 40 mg and 100 mg (irinotecan hydrochloride hydrate) for treatment of pancreatic cancer.

The MHLW officially requested that Daiichi Sankyo develop Topotecin® intravenous drip infusion as a result of discussions by the Review Committee for Unapproved or Off-label Use of Drugs with High Medical Needs(\*1) on March 23, 2012.

As a part of its corporate social responsibility efforts, Daiichi Sankyo is committed to making unapproved or off-label use of drugs with high medical needs available to the patients who need them.

\*1 Working group held by the MHLW that aims to promote the development of drugs and indications not yet approved in Japan, but which are available in Europe and the U.S.